Monitoring Agency Report for Quarter - IV of financial year 2025-26, ended on March 31, 2026
ORCHPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Orchid Pharma Limited submitted its Q4 monitoring agency report for the Rs. 400 crore Qualified Institutions Placement. CARE Ratings Limited, the monitoring agency, confirmed no deviation from the stated objects of the issue. The company revised its allocation of QIP proceeds among various objects with shareholder approval obtained through an AGM resolution dated September 20, 2025. There is significant delay in the Jammu manufacturing facility under Orchid Bio Pharma Limited due to land acquisition challenges, with commercial operations now expected to commence by February 2027. The Alathur API facility block has been fully utilized as of June 2025, and Rs. 3.77 crores has been spent on technical know-how.
The monitoring report shows the QIP funds are being utilized as per revised allocation approved by shareholders. The Jammu facility delay may extend timelines for expected revenue from new manufacturing capacity, though construction is reportedly in advanced stage.